ascopubs.org

Prediction of oncogene mutation status in non-small cell lung cancer leveraging radiomics from CT scans: A systematic review and meta-analysis with a special focus on ...

Spectrum of HER2 alterations in NSCLC: Comparative analysis of tissue and liquid biopsies in lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
ascopubs.org

Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.

Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer. Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational ...
News Medical

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for ...
Medical Xpress

CRISPR approach turns oncogene amplification into a weakness in multiple solid tumors

The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes ...
BioWorld

Sunrise Oncology divulges new interaction inhibitors targeting KRAS mutations

Sunrise Oncology (Hong Kong) Ltd. has synthesized molecular glues acting as GTPase KRAS (and/or its mutant)/RAF proto-oncogene serine/RAF1 interaction inhibitors reported to be useful for the ...

KRAS mutation type may guide more effective cancer treatments

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...